Alterity Therapeutics Ltd. · ASX:ATH
Alterity Therapeutics — Shareholder Meeting (November 2019)
12 slides from Alterity Therapeutics's shareholder meeting presentation, Nov 26, 2019
Slide 1: Alterity Annual General Meeting
le, Alterity @ THERAPEUTICS Alterity Annual General Meeting David Stamler, MD Chief Medical Officer
Slide 2: Clinical Target — Parkinsonian Disorders
Clinical Target — Parkinsonian Disorders *, Alterity Significant unmet medical need > TMenaneumies » Parkinsonian disorders include Parkinson disease and atypical forms such as Multiple system atrophy (MSA) and Dementia with Lewy Bodies « Atypical forms have ancillary symptoms and a limited response
Slide 3: Orphan Designation: PBT434 for the treatment of MSA
Orphan Designation ¢, Alterity PBT434 for the treatment of MSA ° THERareurics » In January 2019, US Food and Drug Administration (FDA) granted Orphan Drug Designation for PBT434 « 7 years of market exclusivity for use of PBT434 in the treatment of MSA « Development incentives of the Orphan Drug Act
Slide 4: Multiple System Atrophy
Multiple System Atrophy th Alterity A form of atypical parkinsonism THERAPEUTICS * Orphan disease MI Map of brain of * No drug approved for treatment of MSA MSA Patient * Characterized by Parkinsonism (motor Frontal symptoms), difficulty maintaining blood acc pressure and/or problems with gait, SN b
Slide 5: PBT434 Targets Alpha-Synuclein
PBT434 Targets Alpha-Synuclein fo Alterity ® THERAPEUTICS ad Biogen Astrazeneca? DOI:10.4236/health.2012.431175 x) = THE MICHAEL |. FOX FOUNDATION FOR PARKINSON'S RESEARCH a-synuclein is an established disease target Abundant protein in the brain ° Critical for normal function of neurons %2 Key prot
Slide 6: Brain Iron Increased in Areas of Pathology
Brain lron Increased in Areas of Pathology te Alterity Parkinson's disease Bi Patients Healthy 0 10000 20000 30000 nmol iron/g of human brain Specialized MRI to Measure Brain Iron MSA Healthy THERAPEUTICS Multiple System Atrophy Cerebral cortex Caudate nucleus Putamen (M) Putamen (L) Globus pallidus
Slide 7: PBT434 is Efficacious in Parkinsonian Disease Animal Models
PBT434 is Efficacious in Parkinsonian Disease Animal Models fly. Alterity THERAPEUTICS wv) a-Synuclein aggregation Preserves nigral neurons Improves motor function Ea 6 8000 ** o a 100: g +e Parkinson’s Ey g . @ @ > disease 3 Fy 2 bE 4000. o Model z 8 50: g 2 a Go g ss cS ® OWT Vehicle PETa34 0 Vehi
Slide 8: Phase 1 Design
Phase 1 Design ¢, Alterity @ THERAPEUTICS ¢ Population: Healthy adult and older adult (265 yo) volunteers 600 me ll 250mg bid A > sme A a > 65 years S/o 200 mg bid 50 mg So 100 mg bid
Slide 9: Plasma and Spinal Fluid Concentrations of PBT434
Plasma and Spinal Fluid Concentrations of PBT434 fly. Alterity Plasma after Single Doses 10000 = o So o 100 10 PBT434 in plasma (ng/mL) 0 12 24 36 48 60 72 Hours post dose Takeaways THERAPEUTICS Spinal Fluid at Steady-State 250 Zz . £ 200 & : _/ os al = 150: el 3 = . i 1. = 2 a a § 100 “ . E = i °=0
Slide 10: Safety of PBT434
Safety of PBT434 te Alterity THERAPEUTICS « All adverse events (AEs) were mild to moderate in severity * No serious AEs or AEs leading to discontinuation in any subject « Headache was the most common AE in subjects receiving 8 days PBT434 ¢ The AE profile was similar for adult and 2 65 year-old volu
Slide 11: Summary
Summary ¢. Alterity THERAPEUTICS Y Targeting Orphan disease with no approved treatments * Potential peak sales of US$750 million (U.S. only) v¥ Development team with proven track record at FDA v Lead drug candidate passed Phase 1 * PBT434 was well tolerated with an AE profile comparable to placebo *
Slide 12: t e Alterity
t e Alterity
Alterity Therapeutics — Shareholder Meeting (November 2019) on 6ix